{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:39:33Z","timestamp":1782380373508,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clinthera.2018.04.015","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T16:34:24Z","timestamp":1527698064000},"page":"993-1013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia"],"prefix":"10.1016","volume":"40","author":[{"given":"Woohyeun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonyee E.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Whan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bum-Kee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Jun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Yong","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Su","family":"Hyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyo-Seung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Won","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hyeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.04.015_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","article-title":"National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants","volume":"377","author":"Farzadfar","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2018.04.015_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","article-title":"Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study","volume":"74","author":"Kannel","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-61-5-888","article-title":"Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study","volume":"61","author":"Kannel","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","article-title":"Cholesterol and coronary heart disease: predicting risks by levels and ratios","volume":"121","author":"Kinosian","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2018.04.015_bib6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.04.015_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.04.015_bib8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.04.015_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2018.04.015_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3803\/EnM.2017.32.1.30","article-title":"Prevalence and clinical characteristics of dyslipidemia in Koreans","volume":"32","author":"Jeong","year":"2017","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2018.04.015_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3349\/ymj.2017.58.2.326","article-title":"Management status of cardiovascular disease risk factors for dyslipidemia among Korean adults","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.clinthera.2018.04.015_bib12","doi-asserted-by":"crossref","first-page":"e000650","DOI":"10.1161\/JAHA.113.000650","article-title":"Serum cholesterol concentration and prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in the Korea National Health and Nutrition Examination Surveys 2008-2010: Beyond the tip of the iceberg","volume":"3","author":"Lee","year":"2014","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.clinthera.2018.04.015_bib13","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1185\/03007995.2014.941979","article-title":"Reaching low density lipoprotein cholesterol targets","volume":"30","author":"Rizos","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.04.015_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1185\/030079906X89856","article-title":"Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe","volume":"22","author":"Daskalopoulou","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.04.015_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bmj.326.7391.689","article-title":"Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices","volume":"326","author":"Hippisley-Cox","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2018.04.015_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1185\/030079905X48447","article-title":"The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel","volume":"21","author":"Mikhailidis","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.04.015_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib18","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2018.04.015_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2018.04.015_bib22","first-page":"995","article-title":"European Action on Secondary Prevention by Intervention to Reduce Events","volume":"357","year":"2001","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2018.04.015_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002280100329","article-title":"Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)","volume":"57","author":"Igel","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.04.015_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/hrt.2006.112508","article-title":"Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials","volume":"93","author":"Afilalo","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2018.04.015_bib26","article-title":"High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy","volume":"Vol 110","author":"Sabatine","year":"2004"},{"key":"10.1016\/j.clinthera.2018.04.015_bib27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2018.04.015_bib28","article-title":"Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption","volume":"Vol 21","author":"Davis","year":"2000"},{"key":"10.1016\/j.clinthera.2018.04.015_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1567-5688(01)80226-9","article-title":"Effect of ezetimibe on serum concentrations of lipid-soluble vitamins","volume":"2","author":"Knopp","year":"2001","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.clinthera.2018.04.015_bib30","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"Van Heek","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.bjp.0704260","article-title":"Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function","volume":"134","author":"Van Heek","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(24)36992-7","article-title":"In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461","volume":"283","author":"Van Heek","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.clinthera.2018.04.015_bib33","article-title":"Ezetimibe, a selective cholesterol absorption inhibitor, improves plasma lipids in hypercholesterolemic patients","volume":"Vol 104","author":"Dujovne","year":"2001"},{"key":"10.1016\/j.clinthera.2018.04.015_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1567-5688(01)80027-1","article-title":"Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Knopp","year":"2001","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.clinthera.2018.04.015_bib35","first-page":"89","article-title":"Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications","volume":"2","author":"Kosoglou","year":"2001","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.clinthera.2018.04.015_bib36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1185\/030079905X50642","article-title":"Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials","volume":"21","author":"Catapano","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.04.015_bib38","first-page":"150","article-title":"Adherence to medication regimens and recommended lifestyle changes in patients with cardiovascular disease","volume":"3","author":"Ziegelstein","year":"2003","journal-title":"Adv Stud Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2018.04.015_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","article-title":"Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy)","volume":"62","author":"Kini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/0091270002042009002","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"White","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.04.015_bib42","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.04.015_bib43","first-page":"441","volume":"9","author":"Foody","year":"2014","journal-title":"Efficacy and safety of ezetimibe plus atorvastatin therapy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818301577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818301577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:57:11Z","timestamp":1751666231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818301577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0149291818301577"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}